Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aminolevulinic acid - DUSA

Drug Profile

Aminolevulinic acid - DUSA

Alternative Names: 5 ALA; 5-Aminolaevulinic acid; 5-Aminolevulinic acid; ALA - DUSA; aminolevulinic acid HCL - DUSA; Delta-aminolevulinic acid; Levulan PDT; Levulan photodynamic therapy; Levulan/Kerastick; Levulan™

Latest Information Update: 24 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PARTEQ Innovations
  • Developer Cleveland Clinic; DUSA Pharmaceuticals
  • Class Amino acids; Antianaemics; Antineoplastics; Diagnostic agents; Imaging agents; Keto acids; Levulinic acids; Nootropics; Skin disorder therapies; Small molecules; Vascular disorder therapies
  • Mechanism of Action Antioxidants; Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Oesophageal dysplasia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Actinic keratosis
  • Phase II Brain cancer; Skin cancer
  • No development reported Barrett's oesophagus; Basal cell nevus syndrome
  • Discontinued Acne vulgaris; Leucoplakia; Oesophageal cancer; Photodamage; Psoriasis

Most Recent Events

  • 06 Jan 2020 No recent reports on development identified - Phase-II for Basal Cell Nevus Syndrome (In adolescents, In children, In adults) in USA (Topical)
  • 26 Dec 2018 DUSA filed a motion for preliminary injunctive relief regarding the patent dispute between DUSA and Biofrontera
  • 24 Jul 2018 DUSA Pharmaceuticals files lawsuit againts Biofrontera for patent infringement, trade secret misappropriation and tortious interferance claims for aminolevulinic acid HCl in the US
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top